MD Anderson Cancer Center/University of Texas MDACC
Welcome,         Profile    Billing    Logout  
 32 Trials 
34 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Meric-Bernstam, Funda
TAPUR, NCT02693535: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Recruiting
2
3791
US
Palbociclib, Ibrance, Sunitinib, Sutent, Temsirolimus, Torisel, Trastuzumab and Pertuzumab, Herceptin and Perjeta, Vemurafenib and Cobimetinib, Zelboraf and Cotellic, Regorafenib, Stivarga, Olaparib, Lynparza, Pembrolizumab, Keytruda, Nivolumab and Ipilimumab, Opdivo and Yervoy, Abemaciclib, Verzenio, Talazoparib, Talzenna, Atezolizumab and PHESGO, Tecentriq and PHESGO, Atezolizumab and Talazoparib, Tecentriq and Talzenna, Entrectinib, Rozlytrek, Larotrectinib, Vitrakvi, Tucatinib plus Trastuzumab Subcutaneous (SC), Tukysa and Herceptin Hylecta, Futibatinib, Lytgobi
American Society of Clinical Oncology, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Merck Sharp & Dohme LLC, Pfizer, Boehringer Ingelheim, Seagen Inc., Taiho Oncology, Inc.
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
12/24
12/25
NCT04946864: A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer

Recruiting
1/2
65
US
APG-2575, APG2575, Palbociclib
Ascentage Pharma Group Inc.
Breast Cancer, Solid Tumor, Adult
07/24
10/24
CBX-12-101, NCT04902872: Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors

Active, not recruiting
1/2
130
US
CBX-12
Cybrexa Therapeutics
Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma, Breast Cancer, Colorectal Cancer, Pancreas Cancer, Appendix Cancer, Non-small Cell Lung Cancer, Gastric Cancer, Esophagus Cancer, Urothelial Carcinoma, Sarcoma
05/24
09/24
ZWI-ZW25-204, NCT05027139: A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer

Active, not recruiting
1/2
52
US
Zanidatamab, ZW25, JZP598, Evorpacept, ALX148
Jazz Pharmaceuticals, ALX Oncology Inc.
HER2-expressing Cancers
10/24
04/25
StarBridge-1, NCT05320588: A Study in Patients With Advanced Cancers

Recruiting
1/2
332
US
BIO-106, Pembrolizumab, Keytruda
BiOneCure Therapeutics Inc.
Advanced Cancer, Advanced Solid Tumor, Cancer, Oncology
04/24
04/27
NCT04092673: Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies

Recruiting
1/2
30
US
eFT226, Selective translation inhibitor, Sotorasib, Lumarkus, Fulvestrant, Faslodex, Abemaciclib, Verzenia, Trastuzumab, Herceptin
Effector Therapeutics
Solid Tumor, Adult
12/24
03/25
NCT05548296: A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

Recruiting
1/2
390
US
ACR-368, prexasertib, Gemcitabine, OncoSignature
Acrivon Therapeutics, GOG Foundation
Platinum-resistant Ovarian Cancer, Endometrial Adenocarcinoma, Urothelial Carcinoma
07/26
12/27
NCT05941507: A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

Recruiting
1/2
300
Canada, US
LCB84, Anti-PD-1 monoclonal antibody
LigaChem Biosciences, Inc., AntibodyChem Biosciences, Inc.
Advanced Solid Tumors
01/27
05/27
FONTANA, NCT05797168: Phase I/IIa Study for AZD5335 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors

Recruiting
1/2
150
Europe, Canada, Japan, US, RoW
AZD5335, AZD5305
AstraZeneca
Ovarian Cancer, Lung Adenocarcinoma
11/27
11/27
NCT04586270: A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer

Recruiting
1
100
Europe, US
TAS0612
Taiho Oncology, Inc.
Advanced or Metastatic Solid Tumors
08/24
07/27
SGNCEA5C-001, NCT06131840: A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

Recruiting
1
410
Canada, US
SGN-CEACAM5C, SAR445953
Seagen Inc., Sanofi
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small Cell Lung Carcinoma
03/29
03/30
NCT06234423: A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

Recruiting
1
180
US
CUSP06
OnCusp Therapeutics, Inc.
Ovarian Cancer, Solid Tumor
05/27
08/27
NCT03843359: A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors

Active, not recruiting
1
98
Europe, Canada, Japan, US, RoW
GSK3745417, Dostarlimab
GlaxoSmithKline
Neoplasms
03/25
03/25
NCT05527184: First in Human Study of IMGN151 in Recurrent Endometrial Cancer and Recurrent, High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers

Recruiting
1
227
US
IMGN151
ImmunoGen, Inc.
Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
06/24
12/25
NCT04706962: TH1902 in Patients With Advanced Solid Tumors

Recruiting
1
70
Canada, US
TH1902, TH1902 peptide-drug conjugate
Theratechnologies, PPD, Altasciences Company Inc., Windtree Therapeutics, Syneos Health, Innovaderm Research Inc.
Solid Tumor, TNBC - Triple-Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Cutaneous Melanoma, Thyroid Cancer, Small-cell Lung Cancer, Prostate Cancer, SORT1+ Cancers
12/24
12/24
NCT05753722: A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

Recruiting
1
270
US
PRTH-101, Pembrolizumab
Incendia Therapeutics
Advanced or Metastatic Solid Tumors
09/27
09/27
NCT04058756: Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments

Recruiting
1
121
Europe, Canada, US, RoW
PDR001
Novartis Pharmaceuticals
Advanced Solid Tumors
04/30
04/30
NCT04507503: Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

Approved for marketing
N/A
US
TAS-120, Futibatinib
Taiho Oncology, Inc.
Advanced Cholangiocarcinoma
 
 
Phillips, Christine
REFUEL, NCT05460533: A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)

Recruiting
2
33
US
Tisagenlecleucel
Memorial Sloan Kettering Cancer Center, Novartis Pharmaceuticals
B-cell Acute Lymphoblastic Leukemia
07/26
07/26
CASSIOPEIA, NCT03876769 / 2017-002116-14: Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

Calendar Jan 2025 - Dec 2025: Data from CASSIOPEIA trial for 1L acute ALL
Recruiting
2
121
Europe, Canada, US
CTL019
Novartis Pharmaceuticals, Children's Oncology Group
B-Cell Acute Lymphoblastic Leukemia
10/27
10/27
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients

Available
N/A
Canada, US, RoW
CTL019, tisagenlecleucel, Kymriah
Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL)
 
 
Drappatz, Jan
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Recruiting
2
124
US
Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
10/24
10/24
INSIGhT, NCT02977780: INdividualized Screening Trial of Innovative Glioblastoma Therapy

Recruiting
2
250
US
Temozolomide, Temodar, Neratinib, QBS10072S
Patrick Wen, MD, Eli Lilly and Company, Celgene, Puma Biotechnology, Inc., Accelerate Brain Cancer Cure, Quadriga Biosciences, Inc.
Glioblastoma
03/25
12/25
PROSPECT, NCT04947319: Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma ( Study)

Recruiting
2
112
US
Tirabrutinib, ONO-4059
Ono Pharmaceutical Co. Ltd
Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma
03/27
03/27
NCT05736406: A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma

Recruiting
1/2
12
US
5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 200 J/cm^2, Pentalafen®, 5-aminolevulinic acid hydrochloride, Heliance® Solution, 5-ALA PDT, 5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 400 J/cm^2
Hemerion Therapeutics
Primary Glioblastoma
03/25
07/25
NCT05109728: A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.

Recruiting
1
60
Europe, US
[177Lu]Lu-DOTA-TATE, Lutathera, Lutetium (177Lu)oxodotreotide, Lutetium Lu 177dotatate, [68Ga]Ga-DOTA-TATE, Temozolomide, Radiotherapy
Novartis Pharmaceuticals
Glioblastoma
07/25
07/26
NCT03423628: A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

Calendar Jan 2024 - Dec 2024: Data from trial in combination with radiation therapy for brain metastases
Recruiting
1
120
Europe, US
Radiation Therapy, Radiotherapy, Radiation treatment, RT, AZD1390, ATM inhibitor
AstraZeneca
Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme, Brain Neoplasms, Malignant, Leptomeningeal Disease (LMD)
04/26
04/26
Majd, Nazanin
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study)

Calendar Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Calendar Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Recruiting
3
450
Europe, Canada, US, RoW
ONC201, ONC201 + Placebo, Placebo
Chimerix
H3 K27M, Glioma
08/26
08/26
NCT05388435: Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients

Terminated
1/2
17
US
SKL27969
SK Life Science, Inc.
Advanced Solid Tumor
03/24
03/24
NCT05109728: A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.

Recruiting
1
60
Europe, US
[177Lu]Lu-DOTA-TATE, Lutathera, Lutetium (177Lu)oxodotreotide, Lutetium Lu 177dotatate, [68Ga]Ga-DOTA-TATE, Temozolomide, Radiotherapy
Novartis Pharmaceuticals
Glioblastoma
07/25
07/26
NCT05804227: Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Low-Grade Gliomas in Adults

Recruiting
1
20
US
Ulixertinib
M.D. Anderson Cancer Center, BioMed Valley Discoveries, Inc
Gliomas
09/25
09/27
NCT04617002: Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas

Available
N/A
US
ONC201 (dordaviprone)
Chimerix
Glioma, H3 K27M
 
 
Drokin, Ashley
NCT04058756: Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments

Recruiting
1
121
Europe, Canada, US, RoW
PDR001
Novartis Pharmaceuticals
Advanced Solid Tumors
04/30
04/30

Download Options